These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27082702)

  • 1. Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma.
    Yang G; Zong H
    Mol Med Rep; 2016 Jun; 13(6):4786-90. PubMed ID: 27082702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
    Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
    Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
    Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Numb promotes hepatic progenitor expansion and intrahepatic cholangiocarcinoma by enhancing Notch signaling.
    Shu Y; Xu Q; Xu Y; Tao Q; Shao M; Cao X; Chen Y; Wu Z; Chen M; Zhou Y; Zhou P; Shi Y; Bu H
    Cell Death Dis; 2021 Oct; 12(11):966. PubMed ID: 34667161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.
    Angenard G; Merdrignac A; Louis C; Edeline J; Coulouarn C
    Dig Liver Dis; 2019 Sep; 51(9):1337-1343. PubMed ID: 31040073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures.
    Bernatz S; Schulze F; Bein J; Bankov K; Mahmoudi S; Grünewald LD; Koch V; Stehle A; Schnitzbauer AA; Walter D; Finkelmeier F; Zeuzem S; Vogl TJ; Wild PJ; Kinzler MN
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):357. PubMed ID: 39034327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
    Yang L; Niu K; Wang J; Shen W; Jiang R; Liu L; Song W; Wang X; Zhang X; Zhang R; Wei D; Fan M; Jia L; Tao K
    J Hepatol; 2024 Oct; 81(4):651-666. PubMed ID: 38679071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing.
    Yang W; Li Y; Song X; Xu J; Xie J
    Oncotarget; 2017 Apr; 8(16):26591-26599. PubMed ID: 28427159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
    Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
    Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma.
    Deng S; Lu X; Wang X; Liang B; Xu H; Yang D; Cui G; Yonemura A; Paine H; Zhou Y; Zhang Y; Simile MM; Urigo F; Evert M; Calvisi DF; Green BL; Chen X
    Cell Death Dis; 2024 Jun; 15(6):441. PubMed ID: 38909034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
    Lixin S; Wei S; Haibin S; Qingfu L; Tiemin P
    Mol Carcinog; 2020 Dec; 59(12):1371-1381. PubMed ID: 33052627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
    Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
    Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
    Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
    Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Yang LX; Gao Q; Shi JY; Wang ZC; Zhang Y; Gao PT; Wang XY; Shi YH; Ke AW; Shi GM; Cai JB; Liu WR; Duan M; Zhao YJ; Ji Y; Gao DM; Zhu K; Zhou J; Qiu SJ; Cao Y; Tang QQ; Fan J
    Hepatology; 2015 Dec; 62(6):1804-16. PubMed ID: 26340507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes.
    Chen Z; Gao J; Li Z; Ma D; Wang Y; Cheng Q; Zhu J; Li Z
    Liver Int; 2024 Sep; 44(9):2477-2493. PubMed ID: 38924592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma.
    Yoo C; Kang J; Kim D; Kim KP; Ryoo BY; Hong SM; Hwang JJ; Jeong SY; Hwang S; Kim KH; Lee YJ; Hoeflich KP; Schmidt-Kittler O; Miller S; Choi EK
    Oncotarget; 2017 Jun; 8(24):38592-38601. PubMed ID: 28445152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
    Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
    PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brahma-Related Gene 1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Zhou Y; Chen Y; Zhang X; Xu Q; Wu Z; Cao X; Shao M; Shu Y; Lv T; Lu C; Xie M; Wen T; Yang J; Shi Y; Bu H
    Hepatology; 2021 Aug; 74(2):797-815. PubMed ID: 33650193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.